Catalog No.
Product Name
Application
Product Information
Citations
-
AMPK Pathway Activator
ALKBH1-IN-3 prodrug is a potent inhibitor of the DNA N6-methyladenine demethylase ALKBH1, functioning primarily through modulation of the AMPK signaling pathway. This prodrug significantly enhances the cellular abundance of 6mA, leading to a reduction in the viability of gastric cancer cells. With its strong cellular activity and favorable in vivo metabolic profile, ALKBH1-IN-3 prodrug is a valuable tool for investigating mechanisms underlying gastric cancer and the role of epigenetic modifications in tumor biology. -
AMPKγ3 Activator
PF-07293893 is an AMPKγ3 activator that enhances cellular energy homeostasis. This compound increases glycogen content, improves lipid oxidation, enhances mitochondrial biogenesis, and promotes vascular repair. It is particularly useful in research applications related to heart failure and metabolic disorders. -
AMPK Activator
AMPK Activator 4 is a selective activator of AMP-activated protein kinase (AMPK) that does not inhibit mitochondrial complex I. This compound enhances AMPK activity specifically in muscle tissues, demonstrating a dose-dependent improvement in glucose tolerance in normal mice. Furthermore, it significantly reduces fasting blood glucose levels and ameliorates insulin resistance in db/db diabetic mice, showcasing its potential as an anti-hyperglycemic agent for diabetes research. -
AMPK Activator/GDF15 Inducer
AMPK Activator 12 is a potent activator of AMP-activated protein kinase (AMPK) and serves as an inducer of growth differentiation factor 15 (GDF15). This compound significantly elevates GDF15 protein levels in human hepatic cells, making it a valuable tool for research into metabolic regulation and cellular stress responses. Its ability to modulate these pathways positions AMPK Activator 12 as a crucial reagent for studies on obesity, diabetes, and related metabolic disorders. -
AMPK Activator
AMPK Activator 1 is a potent activator of AMP-activated protein kinase (AMPK), demonstrating an EC50 of less than 0.1 μM. This compound facilitates the phosphorylation of AMPK, thereby enhancing its activity and promoting cellular energy homeostasis. AMPK Activator 1 is valuable for research applications in metabolism, obesity, diabetes, and cancer studies, where modulation of AMPK signaling pathways may provide therapeutic insights. -
AMPK Activator
AMPK-IN-1 is a potent activator of AMP-activated protein kinase (AMPK), specifically targeting the α2β2γ1 isoform with an EC50 of 551 nM. This compound facilitates the phosphorylation of eEF2 through a mechanism that is independent of mTORC1 signaling. AMPK-IN-1 is valuable for research into metabolic regulation and the cellular energy response, offering insights into the therapeutic potential for conditions related to energy imbalances. -
AMPK Activator
3α-Hydroxymogrol is a triterpenoid derived from Siraitia grosvenorii Swingle, recognized for its ability to activate AMP-activated protein kinase (AMPK). This compound promotes phosphorylation of AMPK, which plays a critical role in cellular energy homeostasis. Research applications include studying metabolic disorders, energy regulation, and potential therapeutic effects in obesity and diabetes. -
AMPK Activator
IQZ23 is an AMPK activator that inhibits adipocyte differentiation through the activation of the AMPK pathway. It demonstrates potent efficacy in reducing triglyceride levels, with an EC50 of 0.033 μM in 3T3-L1 adipocytes. This compound is relevant for research into obesity and associated metabolic disorders, making it a valuable tool for studying metabolic regulation. -
mTOR Inhibitor/AMPK Activator
AMPK/mTOR modulator-1 is a Ginsenoside derivative functioning as both an mTOR inhibitor and AMPK activator. It activates AMPK signaling with a Kd of 4.759 μM, promoting M1-like tumor-associated macrophage polarization while inhibiting M2-like polarization. This compound enhances glycolysis and demonstrates significant anti-inflammatory activity alongside inhibition of tumor progression. AMPK/mTOR modulator-1 is ideal for research focused on colorectal cancer and related metabolic disorders. -
AMPK Activator
AMPK Activator 9 (ZM-6) is a potent activator of AMP-activated protein kinase (AMPK) with an EC50 value of 1.1 µM, primarily targeting the α2β1γ1 subunit. This compound demonstrates significant biological activity in energy metabolism modulation and has applications in research focused on type 2 diabetes. It serves as a valuable tool for elucidating AMPK-related pathways and therapeutic strategies for metabolic disorders. -
AMPK Activator
AMPK activator 8 is a potent activator of AMP-activated protein kinase (AMPK), demonstrating EC50 values of 11, 27, 4, 2, and 4 nM for various AMPK isoforms: rAMPK α1β1γ1, rAMPK α2β1γ1, rAMPK α1β2γ1, rAMPK α2β2γ1, and rAMPK α2β2γ3. This compound is particularly valuable for studying metabolic disorders, specifically type 2 diabetes, by enhancing AMPK activity and modulating glucose metabolism. Its high specificity and efficacy make it an important tool for researchers exploring AMPK-related pathways and therapeutic interventions. -
AMPK Activator
AMPK Activator 6 is a potent activator of AMP-activated protein kinase (AMPK) that enhances its signaling pathway in HepG2 and 3T3-L1 cells. This compound effectively reduces lipid accumulation by significantly lowering triglyceride (TG), total cholesterol (TC), and low-density lipoprotein-C (LDL-C) levels in serum. AMPK Activator 6 is valuable for research into non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome, making it a critical tool for investigating metabolic disorders. -
AMPK Activator
AMPK Activator 10 is a potent activator of AMP-activated protein kinase (AMPK) with an effective concentration (EC150) of 44.3 nM as determined by cell-ELISA. This compound enhances phosphorylation of acetyl-CoA carboxylase (ACC), contributing to its biological effects. AMPK Activator 10 has demonstrated glucose-lowering properties, making it a valuable tool for research in metabolic regulation and related disorders. -
AMPK Activator
JJO-1 is an activator of AMP-activated protein kinase (AMPK) with an EC50 of 1.8 μM. This compound is valuable for research into metabolic disorders, particularly obesity and type 2 diabetes, as it modulates energy homeostasis and enhances glucose uptake. JJO-1 provides a tool for scientists investigating therapeutic strategies aimed at metabolic regulation and improving insulin sensitivity. -
CB1R/AMPK Modulator
CB1R/AMPK Modulator 1 is a potent modulator of the cannabinoid receptor type 1 (CB1R) and adenosine monophosphate-activated protein kinase (AMPK), exhibiting a Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. This compound effectively activates AMPK, leading to significant reductions in food intake and body weight. Additionally, it enhances glucose tolerance and insulin sensitivity, making it a valuable tool for research in metabolic disorders and obesity-related studies. -
AMPK Activator
DBI-2 is an AMPK activator that targets mitochondrial complex I. It disrupts oxidative phosphorylation (OXPHOS), leading to a reduction in ATP generation within mitochondria. DBI-2 demonstrates significant inhibitory effects on the proliferation of colorectal cancer (CRC) cells, making it a valuable tool for investigating metabolic dysregulation in cancer research. -
AMPK Activator
BI-9774 is a potent activator of 5' AMP-activated protein kinase (AMPK), with an IC50 ranging from 12 to 88 nM. This compound is primarily utilized in research focused on metabolic disorders, such as type 2 diabetes and obesity, as well as in cardiovascular disease studies, including myocardial ischemia and heart failure. Its ability to modulate AMPK activity makes it a valuable tool for investigating therapeutic strategies in these areas. -
AMPK Activator
AMPK Activator 2, a fluorine-containing proguanil derivative, targets the AMP-activated protein kinase (AMPK) signaling pathway, enhancing its activation while downregulating the mTOR/4EBP1/p70S6K pathway. This compound exhibits significant anti-proliferative and anti-migratory effects on various human cancer cell lines, including UMUC3, T24, and A549. AMPK Activator 2 is valuable for research focused on cancer metabolism and therapeutic strategies aimed at metabolic regulation in oncology. -
AMPK Activator
AMPK activator 14 is a selective activator of AMP-activated protein kinase (AMPK). This compound has demonstrated the ability to lower fasted glucose and insulin levels in a db/db mouse model of Type II diabetes. It serves as a valuable tool for research into metabolic disorders and the mechanisms of diabetes management. -
AMPK-α1β1γ1 Activator
AMPK-α1β1γ1 activator 1 is a selective agonist for the AMPK-α1β1γ1 isoform, exhibiting an EC50 value of 38.1 nM. This compound serves as an acyl glucuronide metabolite of an Indole-3-carboxylic acid-based AMPK activator and demonstrates direct binding to the human AMPK complex. Its biological activity makes it a valuable tool for research into metabolic disorders such as diabetic nephropathy. -
AMPK Activator.
Galbacin, an AMPK activator, plays a crucial role in regulating cellular energy homeostasis. Isolated from Myristica fragrans (nutmeg), Galbacin effectively stimulates the AMPK enzyme in differentiated C2C12 cells, demonstrating notable anti-cancer properties by inhibiting the proliferation of lymphocytes and tumor cells. Additionally, it shows promise in preventing weight gain in diet-induced mice models, making it relevant for research into metabolic syndromes, including obesity and type 2 diabetes, as well as cancer studies. -
AMPK Activator
D942 is a potent activator of AMP-activated protein kinase (AMPK) that effectively penetrates cell membranes. This compound also exhibits partial inhibition of mitochondrial complex I. D942 has demonstrated significant anti-proliferative effects on multiple myeloma cells, making it a valuable tool for studies focusing on energy metabolism and cancer cell growth regulation. 연구 응용: D942 can be utilized in investigations of AMPK signaling pathways and their role in cancer metabolism. -
AMPK Activator
AMPK Activator 7 (compound I-3-24) is a potent activator of AMP-activated protein kinase (AMPK) with an EC50 value of 8.8 nM. This compound is valuable for investigating diseases linked to AMPK dysregulation, including type 2 diabetes, metabolic syndrome, obesity, hyperglycemia, hypercholesterolemia, and hypertension. Its selective activation of AMPK facilitates research into metabolic regulation and potential therapeutic interventions for these conditions. -
AMPK Activator
AMPK Activator 11 is a potent activator of AMP-activated protein kinase (AMPK) with nanomolar antiproliferative activity against various colorectal cancers (CRCs). By selectively activating AMPK, this compound enhances oxidative phosphorylation (OXPHOS) and inhibits the growth of RKO xenografts. AMPK Activator 11 is valuable for research in anti-tumor mechanisms and metabolic disease pathways. -
AMPK Regulator
4-PivO-NMT chloride is an indole-derived modulator of the AMPK signaling pathway, specifically influencing neurogenesis and neurite outgrowth by regulating AMPK activity. Its biological activity suggests potential applications in studying neurological disorders, pain mechanisms, and inflammatory responses. This compound serves as a valuable tool for researchers investigating the role of AMPK in various cellular processes. -
AMPK/Nrf2 Activator
Ethyl (E)-ferulate is an activator of the AMPK/Nrf2 signaling pathway, demonstrating significant potential in reducing acute lung injury induced by lipopolysaccharide. This compound exhibits antioxidant and free radical scavenging properties, contributing to its anti-inflammatory and neuroprotective effects. Ethyl (E)-ferulate is a valuable tool for research focused on inflammation and neurodegenerative diseases. -
AMPK Activator
AMPK activator C2 is a potent allosteric activator of AMP-activated protein kinase (AMPK). It enhances AMPK activity, which plays a critical role in cellular energy homeostasis and metabolic regulation. This compound is valuable for investigating the mechanisms underlying epilepsy and convulsions, contributing to the understanding of neuroenergetics and potential therapeutic approaches. -
AMPK Activator
IND 1316 is an orally active AMPK activator that effectively crosses the blood-brain barrier. It exhibits neuroprotective properties in preclinical models of Huntington's disease and is applicable in research concerning neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. This compound serves as a valuable tool for investigating AMPK-related pathways and therapeutic strategies in neurological diseases. -
PI4KB Inhibitor
PI4K-IN-2 is a highly selective inhibitor of phosphatidylinositol 4-kinase β (PI4KB) with an IC50 of 0.015 μM. This compound demonstrates significant inhibitory activity and is particularly relevant for research involving human rhinovirus (HRV). Its potential applications extend to studies focusing on the role of PI4KB in viral replication and related signaling pathways. -
PI4K Inhibitor
KAI-407 is an orally active inhibitor targeting Plasmodium PI4K kinase, effectively disrupting multiple stages of the parasite lifecycle. It demonstrates EC50 values of 81 nM against the blood stages of malignant Plasmodium and 88 nM for liver schizonts of P. yoelii. Additionally, KAI-407 exhibits IC50 values of 0.64 μM and 0.69 μM for liver schizonts and dormant bodies of P. cynomolgi, respectively. This compound is valuable for investigating vivax malaria and assessing potential therapeutic strategies against Plasmodium berghei infections. -
PI4K Inhibitor
BF738735 is a selective inhibitor of phosphatidylinositol 4-kinase III beta (PI4KIIIβ), exhibiting an IC50 of 5.7 nM. This compound effectively modulates lipid metabolism and signaling pathways involved in cellular processes. BF738735 is leveraged in research to investigate PI4KIIIβ's role in various diseases, including cancer and viral infections, highlighting its potential for therapeutic development. -
ATR Inhibitor
ATR-IN-31 is a selective ATR kinase inhibitor that exhibits an IC50 of 7 nM, demonstrating its potent activity. This compound functions by specifically inhibiting ATR kinase activity without significantly affecting ATM kinase. ATR-IN-31 has shown efficacy in reducing the viability of prostate cancer cells, making it a valuable tool for research focused on prostate cancer. -
ATM/ DNA-PKcs Inhibitor
XRD-0394 is a highly potent and orally active inhibitor of ATM and DNA-PKcs, exhibiting IC50 values of 0.39 nM and 0.89 nM, respectively. This compound demonstrates selectivity for its target enzymes over other members of the PIKK and PI3K families. In preclinical studies, XRD-0394 has been shown to significantly enhance the cytotoxic effects of ionizing radiation on tumor cells both in vitro and in vivo. Additionally, it can synergize with PARP and topoisomerase I inhibitors, making it a valuable tool for research in cancer treatment and DNA repair mechanisms. -
ATR Substrate
ATR kinase substrate peptide (ASELPASQPQPFSAKKK) functions as a specific substrate for ATR protein kinase, facilitating the detection of ATR kinase activity in biological research. This peptide is instrumental in studying cellular responses to DNA damage and the associated signaling pathways. It plays a critical role in validating ATR kinase activity and exploring its implications in cancer biology and therapeutic development. -
ATR Inhibitor
(S)-Ceralasertib is an ATR inhibitor, specifically targeting ataxia telangiectasia mutated and rad3 related (ATR) signaling pathways. This compound exhibits significant potential in cancer research by enhancing the sensitivity of tumor cells to DNA-damaging agents through inhibition of the ATR pathway. (S)-Ceralasertib is utilized in studies aimed at understanding the roles of DNA repair mechanisms and evaluating combination therapies for various cancers. -
ATM Inhibitor
WSD0628 is a potent ATM inhibitor known for its ability to cross the blood-brain barrier. It exhibits significant radiosensitizing effects, making it a valuable tool for research in cancer therapy and radiobiology. Its inhibition of the ATM pathway has implications for enhancing the efficacy of radiotherapy in various malignancies. -
PROTAC ATR Degrader
PROTAC ATR degrader-1 (compound ZS-7) is a potent degrader targeting ataxia telangiectasia and Rad3-related (ATR) proteins, demonstrated by a DC50 of 0.53 μM. This compound facilitates selective degradation of ATR, making it a valuable tool for cancer research and the study of DNA damage response pathways. Its application in cellular models aids in understanding the therapeutic potential of ATR inhibition in various malignancies. -
ATM Inhibitor
M3541 is a potent, ATP-competitive inhibitor of Ataxia Telangiectasia Mutated (ATM) kinase, exhibiting an IC50 of 0.25 nM. This compound demonstrates significant selectivity against other protein kinases. M3541 effectively hinders the repair of double-strand breaks (DSB) and displays notable antitumor activity, making it a valuable tool for cancer research and therapeutic studies targeting DNA damage response pathways. -
ATM/ATR
SKLB-197 is a selective inhibitor of ATR (ATM and Rad3-related protein) with an IC50 value of 0.013 μM, demonstrating minimal activity against a panel of 402 other protein kinases. This compound exhibits significant antitumor efficacy specifically in ATM-deficient tumors, showing potent activity in both in vitro and in vivo models. SKLB-197 serves as a valuable tool for investigating the roles of ATM and ATR in cancer biology and for the development of targeted therapies. -
ATR Inhibitor
ATR-IN-4 is a selective inhibitor of the ATR (Ataxia Telangiectasia Mutated and Rad3-related) kinase. This compound exhibits significant antiproliferative activity against human prostate cancer cells (DU145) and human lung cancer cells (NCI-H460), yielding IC50 values of 130.9 nM and 41.33 nM, respectively. ATR-IN-4 is valuable for research investigating DNA damage response pathways and potential therapeutic strategies in cancer treatment. -
Atm Inhibitor
ATM Inhibitor-10 is a selective ATM inhibitor characterized as a 3-quinoline carboxamide with an IC50 of 0.6 nM. This compound demonstrates significant anti-tumor activity in SW620 xenograft models and shows synergistic effects when combined with Top I inhibitors. It serves as a valuable tool for studies involving DNA damage response and cancer therapeutics. -
PROTAC ATR Degrader
Abd110 is a Lenalidomide-based PROTAC that targets and degrades ATR kinase. It selectively reduces levels of ATR and phospho-ATR while sparing related kinases such as ATM and DNA-PKcs. This compound is valuable for research applications focused on ATR-mediated pathways and innate cellular responses to DNA damage. -
ATM Kinase Activity Inducer
GJ071 oxalate is an ATM kinase activity inducer that targets ataxia telangiectasia mutated (ATM) kinase. It is specifically designed for use in A-T cells harboring homozygous TGA or TAG stop codons. This compound enhances ATM kinase activity, facilitating studies on DNA damage response mechanisms and therapeutic strategies for ataxia telangiectasia and related disorders. -
ATM Inhibitor
(S)-WSD0628 is a selective ATM inhibitor that effectively inhibits the phosphorylation of ATM in MCF-7 cells, with an IC50 of less than 100 nM. This compound demonstrates radiosensitizing properties, enhancing the efficacy of radiotherapy in cancer treatments. Additionally, (S)-WSD0628 is capable of crossing the blood-brain barrier, making it a valuable tool for research applications in neuro-oncology and other fields where central nervous system exposure is essential. -
ATR Inhibitor
ATR-IN-9 is a selective inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR), with an IC50 value of 10 nM, indicating its high potency. This compound is useful for research applications involving cell cycle regulation, DNA damage response, and cancer therapeutics, offering insights into the role of ATR in cellular processes. Its ability to modulate ATR activity makes it a valuable tool in studies focused on tumor biology and therapeutic resistance. -
ATR Inhibitor
ATR-IN-14 is a potent ATR kinase inhibitor that effectively disrupts ATR signaling pathways by inhibiting CHK1 protein phosphorylation, achieving 98.03% inhibition at 25 nM. With demonstrated anticancer activity in LoVo cells, ATR-IN-14 exhibits an IC50 of 64 nM. This reagent is valuable for researchers investigating DNA damage response mechanisms and therapeutic strategies in cancer treatment. -
ATR Inhibitor
ATR-IN-24 is a potent ATR (Ataxia Telangiectasia and Rad3-related protein) inhibitor. It exhibits significant anticancer activity by interfering with the DNA damage response pathway, thereby enhancing the effects of DNA-damaging agents. This compound is valuable for research applications targeting cancer cell proliferation and sensitivity to chemotherapy, making it an important tool for studies on tumor biology and treatment resistance. -
ATM Inhibitor
ATM Inhibitor-3 is a potent and selective inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, demonstrating an IC50 of 0.71 nM. This compound specifically inhibits the PI3K kinase family, making it relevant for research in cancer biology and DNA damage response pathways. Additionally, ATM Inhibitor-3 exhibits favorable metabolic stability, making it a valuable tool for in vitro and in vivo studies. -
ATR Inhibitor
ATR-IN-6 is a selective inhibitor of ATR (ATM and Rad3-related), a serine/threonine kinase crucial for maintaining genomic stability and facilitating DNA damage repair, belonging to the phosphoinositide 3-kinase-related kinase (PIKK) family. This compound exhibits significant biological activity in the context of ATR-mediated pathways and holds promise for research in proliferative disorders and various cancer types. Its targeted inhibition of ATR can aid in the investigation of therapeutic strategies for diseases associated with DNA damage response dysfunction. -
ATR Inhibitor
ATR-IN-23 is a highly selective inhibitor of ATR (Ataxia Telangiectasia and Rad3-related protein) with an IC50 of 1.5 nM. This compound demonstrates significant antiproliferative activity against LoVo cancer cells and induces synthetic lethality in HT-29 cells. ATR-IN-23 is a valuable tool for investigating the mechanisms of DNA damage response (DDR) in cancer research, particularly in the context of DDR-deficient cancer types.
